ISSN: 2320-480X
Manuscript Submission

The Journal of Phytopharmacology, 2020;9(1):46-53 ;   DOI:10.31254/phyto.2020.9108

Research Article

Network pharmacology-based prediction and experimental validation of Mimosa pudica for Alzheimer's disease

Taaza Duyu1 , NA Khatib1 , Pukar Khanal1 , BM Patil1 , KK Hullatti2

1. Department of Pharmacology and Toxicology, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research (KAHER), Belagavi-590010, India
2. Department of Pharmacognosy and Phytochemistry, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research (KAHER), Belagavi-590010, India

*Author to whom correspondence should be addressed.

Received: 23rd January, 2020 / Accepted: 1st March, 2020

Abstract


Mimosa pudica is a traditional folk medicine and has been reported to improve the memory in experimentally induced amnesia. However, present literature lacks the data for M. pudica compoundprotein interaction with targets related to Alzheimer’s disease (AD) including cytotoxic profile. Hence, the present study aims to evaluate in silico and in vitro antioxidant, cytotoxicity, and acetylcholinesterase inhibitory activity and network evaluation of M. pudica with targets related to Alzheimer’s disease. The whole plant of M. pudica was collected, authenticated and hydroalcoholic extract/fractions were prepared. The antioxidant activity of the hydroalcoholic extract was evaluated by DPPH? free radical scavenging assay (in vitro) and xanthine oxidase binding affinity (in silico). Acetylcholinesterase (AChE) inhibitors from M. pudica were identified from an open-source database and analyzed using a network among compounds, proteins, and modulated pathways. Docking was performed using autodock4 and AChE inhibitory activity of extract/fraction(s) was carried using the in vitro method. The cytotoxicity of M. pudica was assessed using CLC-Pred (in silico) and MTT assay (in vitro). Quercetin-3-O-?-Dxylopyranoside and myricetin-3-O-?-D-xylopyranoside showed the highest binding affinity with xanthine oxidase. AChE was majorly targeted by multiple phytoconstituents of M. pudica. Quercetin showed the highest binding affinity with AChE. Luteolin interacted with maximum proteins involved in the pathogenesis of AD. The compounds were predicted to be more cytotoxic in cancer cells compared to normal. The phytoconstituents from M. pudica were found to be safe in normal cells, and were potent antioxidants. Flavonoids showed highest binding affinity with xanthine oxidase and fraction rich in flavonoids showed the highest AChE inhibitory capacity.

Keywords

Acetylcholinesterase, Alzheimer’s disease, Anti-oxidant, Cytotoxicity, Mimosa pudica


HOW TO CITE THIS ARTICLE

Duyu T, Khatib NA, Khanal P, Patil BM, Hullatti KK. Network pharmacology-based prediction and experimental validation of Mimosa pudica for Alzheimer's disease. J Phytopharmacol 2020; 9(1):46-53.

Creative Commons (CC) License-

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (http://creativecommons.org/licenses/by/4.0/).

Copyright

Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

Technical Support

×